Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Unresectable or Metastatic Breast Cancer
May 13, 2020
Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.
